eGenesis Inc.

https://www.egenesisbio.com

LinkedIn: https://www.linkedin.com/company/egenesisbio

eGenesis’s goal is to transform the field of transplantation by offering safe and effective organs, tissues, and cells to patients in need. The company harnesses cutting-edge gene editing technologies to address the key issues that have impeded xenotransplantation to date. eGenesis’s development pipeline includes lead programs for kidney and islet cell transplant as well as earlier-stage programs focused on other solid organs. *

	Start	2015-02-01 established
	Group	eGenesis (Group)
	Industry	genome editing (gene editing)
	Industry 2	xenotransplantation
	Person	Sekhri, Paul J. (eGenesis 201901– CEO before Lycera + Sanofi + Teva + TPG Biotech + Cerimon + Ariad + Sprout)

	Region	Cambridge, MA
	Country	United States (USA)
	Street	300 Technology Square Suite 301
	City	02139 Cambridge, MA
		Address record changed: 2024-01-05

Basic data	Employees	n. a.

		* Document for »About Section«: eGenesis Inc.. (3/2/21). "Press Release: eGenesis Announces $125 Million Series C Financing". Cambridge, MA.

		Record changed: 2023-07-10

Picture Berlin Partner BIO 2024 International Convention San Diego 650x200px

More documents for eGenesis (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]